Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy

Survivin-2B was specifically expressed in lung cancer tissue, and found to specifically elicit a cellular immune response in lung cancer patients and therefore it may be a novel candidate for peptide vaccination.